Clinical trials: Bone Tumour
AML, Adult, Myelodysplastic Syndromes
EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2
This open-label Phase I study aims to define the recommended dose for further clinical development the NKR-2 treatment administered concurrently with AZA in treatment-naïve AML/MDS patients not candidates for intensive…
- Trial name
- EPITHINK (NCT03612739)
- Testing
- NKR-2 CAR-T Cells
- Sponsor
- Celyad Oncology SA
Orbital Neoplasms
Risk Stratification of Orbital Tumors Based on MRl and Artificial Intelligence
Orbital tumors can be categorized into benign and malignant tumors, and there are significant variations in their biological behavior, treatment, and prognosis.
- Trial name
- NCT06336499
- Testing
- Multi-parametric MRI and image analysis by deep learning or machine learning algorithms
- Volunteers
- 600 people
- Sponsor
- Beijing Tongren Hospital
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
The purpose of this study is to find out whether Cord Blood Transplantation/CBT as the first or second transplant is an effective treatment for children and young adults with blood cancer.
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma
- Trial name
- NCT07566377
- Testing
- Cord Blood Units, Total Body Irradiation, Cyclophosphamide
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia
Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Giving combination chemotherapy before a peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00004128
- Testing
- aldesleukin, filgrastim, busulfan
- Volunteers
- 2,000 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Sarcoma
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy and Spectroscopy-based Molecular Urinalysis in Sarcoma Patients
The purpose of this research study is to see how well Low Pass Whole Genome Sequencing (LP-WGS) can detect circulating tumor deoxyribonucleic acid (ctDNA) in the blood of participants who have bone or soft tissue sarcoma (type of…
- Trial name
- NCT06958107
- Testing
- Non-Metastatic and Resectable, Metastatic and Un-resectable, No evidence of disease, under surveillance
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Wake Forest University Health Sciences
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia
This randomized phase I trial is studying the side effects and best dose of two different schedules of sorafenib in treating patients with refractory or relapsed acute leukemia, myelodysplastic syndromes, or blastic phase chronic…
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia
- Trial name
- NCT00217646
- Testing
- Sorafenib Tosylate
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Myelofibrosis
Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome
The goal of this clinical research study is to learn if using a combination of fludarabine, busulfan, and antithymocyte globulin (ATG) can help to control myelofibrosis or myelodysplastic syndrome in patients receiving a bone…
- Trial name
- NCT00475020
- Testing
- Busulfan, Fludarabine, Thymoglobulin (ATG)
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- M.D. Anderson Cancer Center
Bone Sarcoma, Osteosarcoma
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
Randomized, non-comparative, multicentre exploratory phase II study. Two arms concerning patients with bone sarcoma after the first line therapy: in the first arm, patients will be treated with Regorafenib for a maximum of 12…
- Conditions
- Bone Sarcoma, Osteosarcoma, Ewing Sarcoma, Chondrosarcoma
- Trial name
- REGOSTA (NCT04055220)
- Testing
- Treatment by Regorafenib, Surveillance
- Where
- 16 sites in France
- Volunteers
- 168 people
- Sponsor
- Centre Leon Berard
Prostate Cancer, Advanced Prostate Cancer
European Registry of Next Generation Imaging in Advanced Prostate Cancer
The RING study is a European registry collecting real-world data on advanced prostate cancer (APC) imaging. It aims to evaluate the role of next-generation imaging (NGI), such as PET/CT and whole-body MRI, in detecting and…
- Conditions
- Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)
- Trial name
- RING (NCT06866782)
- Testing
- Imaging
- Where
- 24 sites in Belgium, France and 6 more
- Volunteers
- 600 people
- Sponsor
- Fundacio Puigvert
Leukemia
Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Low doses of interferon alfa may be as effective as high doses.
- Trial name
- NCT00002869
- Testing
- recombinant interferon alfa, cytarabine, hydroxyurea
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- Medical Research Council
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
This protocol will allow ponatinib with refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia
- Trial name
- NCT04233346
- Testing
- Ponatinib 30mg OD, Ponatinib 45mg OD
- Where
- 14 sites in China
- Volunteers
- 93 people
- Sponsor
- Otsuka Beijing Research Institute
Relapsed or Refractory Multiple Myeloma
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Compare efficacy of 56 mg/m2 carfilzomib administered once-weekly in combination with lenalidomide and dexamethasone (KRd 56 mg/m2) to 27 mg/m2 carfilzomib administered twice-weekly in combination with lenalidomide and…
- Trial name
- ARROW2 (NCT03859427)
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- 108 sites in United States, Austria and 15 more
- Volunteers
- 454 people
- Sponsor
- Amgen
CML, Chronic Phase
A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
It's a double-blind , randomized ,multi-center study. The purpose of this study is to explore the efficacy and safety of flumatinib 400mg once daily (QD) versus 600mg QD as the first line therapy in patients with chronic myleiod…
- Trial name
- NCT05353205
- Testing
- Flumatinib mesylate tablets (400mg), Flumatinib mesylate tablets (600mg)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Leukemia
Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify genes related to cancer.
- Trial name
- NCT00897182
- Testing
- microarray analysis, polymerase chain reaction
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms
RATIONALE: Zoledronate may be able to prevent bone metastases caused by prostate cancer. It is not yet known if zoledronate is effective in preventing the spread of prostate cancer to the bones.
- Trial name
- NCT00005073
- Testing
- zoledronic acid
- Where
- United States
- Volunteers
- 544 people
- Sponsor
- Novartis Pharmaceuticals
Biochemically Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy
This phase II trial studies how well 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) works in detecting the spread of cancer to the bones (bone metastasis) in patients with prostate cancer and increased…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8
- Trial name
- NCT04928820
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer Metastatic, Bone Metastases
uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to investigate the applicability of urokinase plasminogen activator receptor (uPAR) Positron Emission Tomography (PET) / CT molecular imaging in patients with metastatic castration-resistant prostate…
- Trial name
- NCT02964988
- Testing
- Injection of PET tracer 68Ga-NOTA-AE105, PET/CT
- Where
- Denmark
- Volunteers
- 17 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Leukemia, Aplastic Anemia
Methadone as an Alternative Treatment for Children Underdoing HSCT
Mucositis is a normal side effect of stem cell transplant which happens as a result of chemotherapy being given prior to a new donor cell infusion (bone marrow transplant).
- Conditions
- Leukemia, Aplastic Anemia, Bone Marrow Failure Syndromes, SCID
- Trial name
- MATCH (NCT06940570)
- Testing
- PCA plus methadone (Experimental), PCA Alone (SOC)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
Prostate Cancer
Phase III Radium 223 mCRPC-PEACE III
The primary objective of the trial is to assess if upfront combination of enzalutamide and Ra223 improves radiological progression-free survival (rPFS1) by investigator assessment compared to enzalutamide single agent in…
- Trial name
- PEACE III (NCT02194842)
- Testing
- Ra223, Enzalutamide
- Where
- 64 sites in Belgium, Brazil and 10 more
- Volunteers
- 446 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostatic Neoplasms, Bone Density
Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
The purpose of this study is to assess the effect of zoledronic acid on bone mineral density in prostatic cancer patients currently receiving androgen deprivation therapy.
- Trial name
- NCT00489905
- Testing
- Zolderonic acid (Zometa)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Hospital Authority, Hong Kong
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.